Anti-Arthritic Effects of Magnolol in Human Interleukin 1β-Stimulated Fibroblast-Like Synoviocytes and in a Rat Arthritis Model by Wang, Jyh-Horng et al.
Anti-Arthritic Effects of Magnolol in Human Interleukin
1b-Stimulated Fibroblast-Like Synoviocytes and in a Rat
Arthritis Model
Jyh-Horng Wang
1, Kao-Shang Shih
2, Jing-Ping Liou
3, Yi-Wen Wu
1, Anita Shin-Yuan Chang
4, Kang-Li
Wang
4, Ching-Lin Tsai
1, Chia-Ron Yang
4*
1Department of Orthopedic Surgery, National Taiwan University Hospital, Taipei, Taiwan, 2Orthopedic Department, Shin Kong Wu Ho-Su Memorial Hospital, Taipei,
Taiwan, 3School of Pharmacy, Taipei Medical University, Taipei, Taiwan, 4School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan
Abstract
Fibroblast-like synoviocytes (FLS) play an important role in the pathologic processes of destructive arthritis by producing a
number of catabolic cytokines and metalloproteinases (MMPs). The expression of these mediators is controlled at the
transcriptional level. The purposes of this study were to evaluate the anti-arthritic effects of magnolol (5,59-Diallyl-biphenyl-
2,29-diol), the major bioactive component of the bark of Magnolia officinalis, by examining its inhibitory effects on
inflammatory mediator secretion and the NF-kB and AP-1 activation pathways and to investigate its therapeutic effects on
the development of arthritis in a rat model. The in vitro anti-arthritic activity of magnolol was tested on interleukin (IL)-1b-
stimulated FLS by measuring levels of IL-6, cyclooxygenase-2, prostaglandin E2, and matrix metalloproteinases (MMPs) by
ELISA and RT-PCR. Further studies on how magnolol inhibits IL-1b-stimulated cytokine expression were performed using
Western blots, reporter gene assay, electrophoretic mobility shift assay, and confocal microscope analysis. The in vivo anti-
arthritic effects of magnolol were evaluated in a Mycobacterium butyricum-induced arthritis model in rats. Magnolol
markedly inhibited IL-1b (10 ng/mL)-induced cytokine expression in a concentration-dependent manner (2.5–25 mg/mL). In
clarifying the mechanisms involved, magnolol was found to inhibit the IL-1b-induced activation of the IKK/IkB/NF-kB and
MAPKs pathways by suppressing the nuclear translocation and DNA binding activity of both transcription factors. In the
animal model, magnolol (100 mg/kg) significantly inhibited paw swelling and reduced serum cytokine levels. Our results
demonstrate that magnolol inhibits the development of arthritis, suggesting that it might provide a new therapeutic
approach to inflammatory arthritis diseases.
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Introduction
Inflammatory arthritis is a synovial disease characterized by
chronic inflammation of the joints and can result in disability
owing to joint destruction. Proliferative fibroblast-like synoviocytes
(FLSs) play crucial roles in both the propagation of inflammation
and joint damage, as they produce large amounts of pro-
inflammatory mediators, such as interleukin (IL)-1, IL-6, tumor
necrosis factor-a (TNF-a), matrix metalloproteinases (MMPs), and
prostaglandin E2 (PGE2) [1]. These mediators bind to specific
receptors, causing gene transcription, and form complicated
signaling interactions which contribute to the progression of
inflammatory arthritis, e.g. leukocyte infiltration, cytokine net-
works formation, cartilage catabolism elevation and anabolism
suppression [2]. Non-steroidal anti-inflammatory drugs (NSAIDs)
are the principal treatment for arthritis patients; however, they
only inhibit cyclooxygenases (COXs) and reduce prostaglandin
generation and have no effect on the production of inflammatory
cytokines [3]. In addition, anti-inflammatory agents carry the risk
of gastrointestinal toxicity. A new generation of NSAIDs, such as
rofecoxib, has been developed with the aim of avoiding adverse
gastrointestinal effects, but rofecoxib had to be withdrawn from
the market due to cardiovascular toxicity. Furthermore, although
some biologic agents, such as etanercept and infliximab, have
provided major advances in treatment, they are expensive and
must be injected subcutaneously or intravenously, which, in turn,
increases the risk of infection [4]. Thus, side-effects remain one of
the problems of the long-term use of NSAIDs and there is a need
for safe and effective anti-arthritic agents for long-term use. Recent
study showed that piascledine, mixture of nonsaponifiable
components of avocado and soybean oils, exerts promising effect
to relief inflammatory arthritis symptoms [5]; several groups also
have studied small anti-inflammatory molecules derived from
natural sources [6,7] with the aim of developing new treatments,
but scientific evidence of their anti-arthritic efficacy is still
insufficient.
The biphenyl neolignan magnolol (5,59-Diallyl-biphenyl-2,29-
diol) is purified from the commonly used Chinese medicinal herb
Magnolia officinalis, which has long been used for the treatment of
fever, headache, asthma, anxiety, and diarrhea [8]. Since the
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than 240 mg/kg body weight per day in a 90 day study in rats, it
has been classified as no safety concern food additives by World
Health Organization [9]. Magnolol has been shown to possess a
range of pharmacological effects, including an anti-inflammatory
effect [10], anti-thrombotic effect [11], anti-tumor effect [12,13], a
platelet aggregation inhibitory effect [11,14], and anti-oxidant
activity [15]. It has been shown to suppress the expression of
inducible nitric oxide synthase [16] and COX-2 by macrophages
[17], reduce the production of the atherosclerosis mediators
monocyte chemotactic protein-1 and vascular cell adhesion
molecule-1 by endothelial cells [18], and inhibit secretion of
MMPs, IL-8, and TNF-a by different cell types [19,20].
Interestingly, no severe side effects of magnolol have been
reported. These effects of magnolol would seem to be beneficial
for chronic inflammatory diseases, for example, inflammatory
arthritis, but, to our knowledge, the anti-arthritic efficacy of
magnolol has never been evaluated.
The present study was performed to examine the inhibitory
effect of magnolol on the expression of pro-inflammatory cytokines
and enzymes in IL-1b-stimulated FLS and to elucidate the
underlying mechanisms. Magnolol was found to reduce IL-1b-
induced IL-6, COX-2, MMP-1, and MMP-13 expression and
these effects correlated with its inhibition of NF-kB and MAPK
activation. Furthermore, studies using an adjuvant-induced
arthritis rat model showed that magnolol inhibited the develop-
ment of arthritis, suggesting its potential as a therapeutic agent in
inflammatory arthritis.
Results
Magnolol suppresses inflammatory mediator production
by IL-1b-stimulated FLS
To examine the anti-inflammatory effect of magnolol, FLS were
stimulated with 10 ng/mL of IL-1b in the presence or absence of
magnolol. As shown in figure 1, addition of IL-1b not only
significantly increased mRNA (Figure 1A) and protein
(Figure 1B and C) levels of IL-6, COX-2, MMP-1, and
MMP-13 (both overexpress in inflammatory arthritis cartilage
and are rate-limiting components of the collagen degradation
process), but also increased production of PGE2 protein
(Figure 1B). Interestingly, magnolol pre-treatment markedly
inhibited the IL-1b-induced increase in IL-6, COX-2, MMP-1,
and MMP-13 mRNA and protein and PGE2 secretion in a
concentration-dependent manner (Figure 1A–C). This inhibition
was not due to decrease total protein levels, since b-actin levels
were unchanged (Figure 1B) and none of the treatments had any
significant effect on cell viability at 24 h, assessed using the MTT
assay (Figure 1D).
Magnolol inhibits NF-kB and MAPK signaling in IL-1b-
activated FLS
The NF-kB and MAPKs pathways play pivotal roles in the
expression of inflammatory mediators by IL-1b-stimulated FLS
and contribute to inflammatory arthritis [21,22]. To further
characterize the molecules involved in the inhibitory effect of
magnolol, we examined whether magnolol regulated these
signaling pathways. FLS were treated with magnolol (0–25 mg/
mL) for 30 min prior to stimulation with 10 ng/mL of IL-1b in
the continued presence of magnolol for different time periods, then
levels of the phosphorylated or total forms of IKKa/b,I kBa, and
p65 were measured using Western blotting. IL-1b treatment for
30 min not only caused significant phosphorylation of IKKa/b at
serine 180/181, phosphorylation of IkBa at serine 32, and IkBa
degradation, but also increased phosphorylation of p65
(Figure 2A). Interestingly, magnolol pre-treatment markedly
inhibited all four effects in a concentration-dependent manner
(Figure 2B). The result of a promoter activity assay showed that
magnolol caused concentration-dependent inhibition of IL-1b-
mediated NF-kB promoter activation (Figure 2C). Furthermore,
after 1 h treatment with IL-1b, a significant increase in NF-kB-
DNA binding activity was seen in an EMSA (Figure 2D) and a
dramatic increase in the translocation of NF-kB into the nucleus
was observed by laser confocal microscopy (Figure 2E) and both
effects were markedly inhibited by addition of magnolol
(Figure 2D and E). IL-1b treatment also resulted in a significant
increase in phosphorylation of JNK, p38, and ERK (Figure 3A),
c-fos promoter activation (Figure 3C), AP-1-DNA binding
activation (Figure 3D), and c-fos nuclear translocation
(Figure 3E) and all of these effects were markedly inhibited by
magnolol (Figure 3B–E). Together, these results demonstrate that
magnolol significantly inhibited the NF-kB and MAPK pathways
and NF-kB, AP-1 nuclear translocation.
Magnolol suppresses the development of arthritis in an
AIA (adjuvant-induced arthritis) model
Our results showing that magnolol inhibited the production of
inflammatory mediators through the NF-kB and MAPKs
pathways strongly suggested that it might be effective in preventing
the pathogenesis of destructive arthritis. We therefore examined
the effect of magnolol in vivo by monitoring the progression and
severity of an AIA model. As shown in figure 4A–C, compared to
the vehicle-treated group, the group treated with 100 mg/kg of
magnolol for 16 days not only showed significantly reduced limb
swelling and paw volumes, but also markedly less leukocyte
infiltration and synovitis. Treatment with magnolol did not affect
the body weight loss (Figure 4D), suggesting that magnolol did
not cause a toxic response. Furthermore, ELISA assays showed
that magnolol caused a significant decrease in serum levels of IL-
1b, IL-6, and PGE2 (Figure 4E). These findings suggest that
magnolol has potent anti-arthritic effects in vivo.
Discussion
Natural products have proved to be a valuable source of new
therapeutic agents. A number of in vitro and in vivo studies have
shown that magnolol has anti-inflammatory activities by inhibiting
inflammatory mediator secretion [16–20] and suppressing inflam-
matory pain [23]. Another component of Magnolia officinalis,
honokiol, was recently reported to inhibit the type II collagen-
induced increase in pro-inflammatory cytokine and MMPs levels
and to suppress type II collagen-induced arthritis [24], raising the
possibility that magnolol may also be useful in the treatment of
inflammatory arthritis. In the present study, magnolol not only
significantly inhibited the IL-1b-induced increase in IL-6, PGE2,
MMP, and COX-2 protein levels, but also remarkably alleviated
M. butyricum-induced arthritis in vivo by inhibiting the NF-kB and
AP-1 signaling pathways, suggesting its potential therapeutic use as
a novel topical anti-arthritic agent. Previous report has indicated
magnolol with low toxicity [8]; however, there was reported that
high concentration of magnolol (10 mg/mL) pretreatment at
30 min before cold preservation (4uC) induces in vitro hepatotox-
icity in rat hepatocyte clone-9 cell line under serum-reduced
conditions [25]. Since low temperature may slow down or
completely discontinue translational and transcriptional machin-
eries in cold preservation cells, so that de novo synthesis (e.g.
magnolol-mediated anti-apoptotic proteins (Bcl-xL) up-regulation
[26]) could not be expected. Furthermore, this experiment
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conditions, the same group also reported that magnolol effectively
improved hepatic function and hepatocyte viability from warm
ischemia-reperfusion injury in rats [26]. In addition, although
PGE2 levels were down-regulated in response to administration of
magnolol, recent study indicated that it is difficult to attribute the
GI damage to one factor, PGs inhibition [27]. Further research is
necessary to demonstrate the GI effect of magnolol.
IL-1b, the major mediator involved in inflammatory arthritis,
can stimulate fibroblast proliferation and increase production of
cytokines and enzymes, which, in turn, activate macrophages and
lead to continued cytokine production [2–4]. This creates a
Figure 1. Magnolol inhibits the IL-1b-induced production of pro-inflammatory mediators in a concentration-dependent manner. (A)
1610
6 fibroblast-like synoviocytes (FLS) were treated with magnolol (0–25 mg/mL) for 30 min, then were incubated for 5 h with or without 10 ng/mL
of IL-1b in the continued presence of magnolol, then levels of IL-6, COX-2, MMP-1, and MMP-13 mRNAs were measured by RT-PCR. (B, C) FLS were
incubated with magnolol (0–25 mg/mL) for 30 min, then with IL-1b (10 ng/mL) for 24 h in the continued presence of magnolol, then supernatants
were assayed for (B) IL-6 or PGE2 or (C) MMP-1 or MMP-13 by ELISA; and the whole cell extracts were subjected to Western blot analysis for COX-2 (B).
(D) Viability of FLS determined after 24 h treatment with 0.25–25 mg/mL of magnolol compared to the control group using the MTT assay. In (B)–(D),
the data are the mean 6 standard error of the mean (SEM), with n=3. * p,0.05 and ** p,0.01 compared to the indicated groups.
doi:10.1371/journal.pone.0031368.g001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31368Figure 2. Magnolol inhibits NF-kB activation in IL-1b-stimulated FLS. FLS (1610
6 cells) were treated with or without 10 ng/mL of IL-1b for
the indicated times (A) or were treated with 0–25 mg/mL of magnolol for 30 min, then stimulated with 10 ng/mL IL-1b for 30 min in the continued
presence of magnolol (B), then the cells were harvested and whole cell extracts subjected to Western blot analysis for the indicated proteins. (C) Cells
(1610
5 cells) were transiently transfected with 1 mg of pGL4.32[luc2P/NF-kB-RE/Hygro] for 24 h and treated with 0–25 mg/mL magnolol for 30 min
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cells that aggravates synovial inflammation and results in joint
destruction. Thus, targeting the intracellular pathways between
activated cytokine receptors and gene expression might be an
attractive strategy for the treatment of inflammatory arthritis, since
different pro-inflammatory mediators can share the same signaling
pathway [2]. The two principal pathways activated by IL-1 are the
NF-kB and MAPK pathways and the roles of both in the
pathogenesis of destructive arthritis have been studied [2–4]. In
most nonstimulated cells, NF-kB exists as an NF-kB/IkB complex
in the cytoplasm; but, in response to the activation of pro-
inflammatory cytokines, IkB is phosphorylated by IkB kinases and
this results in free NF-kB, which can translocate into the nucleus
and induce the transcription of inflammatory cytokines and
mediators [3,4]. A recent study using an adenovirus vector
encoding IkBa showed that overexpression of IkBa inhibits the
production of pro-inflammatory cytokines, MMPs, and aggreca-
nases [28], while another group demonstrated that mice lacking
functional NF-kB-inducing kinase are resistant to AIA [29].
Furthermore, a potent NF-kB inhibitor, curcumin, which is
derived from the dietary turmeric and forms a curcumin-
phosphatidylcholine complex, is under clinical trial evaluation in
osteoarthritis patients [30]. Another major transcription factor that
contributes to the pathogenesis of arthritis is c-fos/AP-1, since c-
fos/AP-1 not only directly controls the expression of inflammatory
cytokines and MMPs by binding to AP-1 motifs in the promoters
of these genes [31], but participates in a cross-talk with IL-1b to
influence each other’s gene expression and activity [32,33]. These
results suggest the IL-1-stimulated NF-kB and MAPK signaling
pathways as potential therapeutic targets in inflammatory arthritis.
Magnolol was found to suppress TNF-a-induced activation of NF-
kB and AP-1, two transcription factors that regulate gene
expression in human monocytes [19] and in vascular smooth
muscle cells [34]. Our results showed that magnolol significantly
inhibited the IL-1b-induced increase in cytokine and MMP
expression and markedly inhibited the IL-1b-induced phosphor-
ylation of IKK/IkB/p65, MAPKs and p65, c-fos DNA-binding
activity and nuclear translocation; suggesting that magnolol exerts
its potent anti-inflammatory activity through its dual inhibitory
effects on cytokines and inflammatory mediators by regulating the
NF-kB and MAPKs pathways.
We also used an AIA model to evaluate the in vivo anti-arthritic
effect of magnolol. Injection of rats with killed M. butyricum
suspended in complete Freund’s adjuvant induces autoimmune
process [35] and increases inflammatory mediators, including IL-
1b, overexpression [36]. In our study, marked swelling of the right
(injected) paw was seen on day 2 and of the left paw on day 9, then
swelling of both paws gradually increased up to the end of the
experiment on day 16. Leukocyte infiltration, synovitis, and
elevated serum cytokine levels were observed in the vehicle-treated
group and were much improved by administration of magnolol
(100 mg/kg). Previous study observed similar result that magnolol
inhibits Mac-1 (CD11b/CD18)-dependent neutrophil adhesion
[37], suggest magnolol inhibits leukocyte infiltration through
suppressing adhesion molecules expression.
Our observations provide evidence that magnolol exerts anti-
arthritic effects by inhibiting the expression of the IL-1b-
stimulated IL-6, COX-2, MMP-1, and MMP-13 inflammation-
associated genes by suppressing the NF-kB and MAPKs pathways.
This inhibitory effect results in an improvement in arthritic
symptoms in vivo. Since inflammatory cytokines and MMPs play
important roles in destructive arthritic disease, this suggests that
magnolol might be a potential anti-arthritic agent.
Materials and Methods
Materials
Magnolol, with a purity greater than 98.65%, was purchased
from Hanhong Chemical CO., Ltd. (Shanghai, China). Its structure
is shown in Figure 5. Rabbit monoclonal antibodies against COX-
2, IKKa,I kBa, and JNK1 were purchased from Epitomics Inc.
(Burlingame, CA, USA). Rabbit polyclonal antibodies against
phosphor-IKKa (Ser180)/IKKb (Ser181), phosphor-ERK1/2
(Thr202/Tyr204), phosphor-p38 (Thr180/Tyr182), ERK1/2, c-
fos, and rabbit monoclonal antibodies against phosphor-IkBa
(Ser32), phosphor-p65 (Ser536), and phosphor-JNK (Thr183/
Tyr185) were purchased from Cell Signaling Technology (Danvers,
MA, USA). Mouse monoclonal anti-NF-kB p65 antibody was
obtained from BioVision (Mountain View, CA, USA). Horseradish
peroxidase (HRP)- or fluorescein isothiocyanate (FITC)- conjugated
goat anti-mouse or anti-rabbit IgG antibodies were obtained from
Jackson ImmunoResearch Inc. (West Grove, PA, USA). ELISA kits
for human IL-6, MMP-1, and MMP-13 and for mouse IL-1b and
IL-6 and a prostaglandin E2 immunoassay kit were purchased from
R&D Systems (Minneapolis, MN, USA). The pGL4.32[luc2P/NF-
kB-RE/Hygro] and p5xATF6-GL3 vectors were obtained from
Promega Corp. (Madison, WI, USA) and Addgene Inc. (Cam-
bridge, MA, USA), respectively. TurboFect
TM in vitro transfection
reagent was purchased from Fermentas (Burlington, Ontario,
Canada). NF-kB and AP-1 EMSA kits were purchased from
Affymetrix, Inc. (Fremont, CA, USA). All other chemicals were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture
Human FLS were derived from the synovial tissues of patients
with osteoarthritis undergoing total joint replacement surgery after
approval by the Ethics Committee of National Taiwan University
Hospital (IRB number: 201106100RC), and the patients gave
their written informed consent. The cells were cultured in 100 mm
dishes in high glucose DMEM medium supplemented with 10%
(v/v) heat-inactivated fetal bovine serum (FBS) (both from
Invitrogen
TM Life Technologies, Carlsbad, CA, USA), 100 U/
mL of penicillin, and 100 mg/mL of streptomycin (Biological
Industries, Kibbutz Beit Haemek, Israel) at 37uC in a humidified
atmosphere of 5% CO2 in air. Cells from passages four to eight
were used for the experiments.
Cell viability assays
Cells (1610
4) in 100 mL of medium in 96-well plates were
incubated with vehicle or test compound for 48 h, then 25 mLo fa
prior to stimulation with 10 ng/mL of IL-1b in the continued presence of magnolol for a further 6 h, then luciferase activity was measured as
described in the Materials and Methods. The results are expressed as the mean 6 standard error of the mean (SEM), with n=3. * p,0.05 compared to
the control group; #p,0.05 for comparison of indicated groups. (D) FLS were incubated with vehicle or 10 ng/mL of IL-1b or were pretreated with
25 mg/mL of magnolol for 30 min, then incubated with IL-1b in the continued presence of magnolol for 1 h, then the DNA binding activity of the
nuclear extracts was examined in an electrophoretic mobility shift assay using a specific NF-kB DNA probe. (E) Cells (1610
5 cells) were left untreated
or were treated with 25 mg/mL of magnolol for 30 min, then stimulated with 10 ng/mL of IL-1b in the continued presence of magnolol for 1 h, when
samples were prepared for confocal microscopy analysis. Scale bar=20 mm.
doi:10.1371/journal.pone.0031368.g002
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31368Figure 3. Magnolol inhibits MAPK pathways and c-fos nuclear translocation. Cells were treated with 10 ng/mL of IL-1b for different time
periods (A) or were treated with magnolol at the indicated concentration for 30 min, then stimulated with IL-1b in the continued presence of
magnolol for 30 min (B). The cells were then harvested and whole cell extracts prepared for Western blot analysis for the indicated proteins. (C) Cells
(1610
5 cells) were transiently transfected with 1 mg of p5xATF6-GL3 for 24 h, then incubated with 0–25 mg/mL magnolol for 30 min before activation
with 10 ng/mL of IL-1b in the continued presence of magnolol for another 6 h, when luciferase activity was measured as described in the ‘‘Materials
and Methods’’. The results are expressed as the mean 6 standard error of the mean (SEM), with n=3. * p,0.05 compared to the control group;
#p,0.05 for the comparison of the indicated groups. (D) Cells were incubated with vehicle or IL-1b (10 ng/mL) for 1 h or were pretreated with
25 mg/mL of magnolol for 30 min, then stimulated with IL-1b in the continued presence of magnolol for 1 h. Nuclear extracts were then subjected to
a DNA-binding reaction with oligonucleotides specific for AP-1. The specific DNA-binding activity of the AP-1 complex is indicated by an arrow. (E)
Cells (1610
5 cells) were incubated with or without 25 mg/mL of magnolol for 30 min, then stimulated with 10 ng/mL of IL-1b in the continued
presence of magnolol for 1 h, when samples were prepared for confocal microscopy analysis. Scale bar=20 mm.
doi:10.1371/journal.pone.0031368.g003
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tetrazolium bromide (MTT) was added and the mixture incubated
at 37uC for 2 h. The cells were then pelleted and lysed in 100 mL
of dimethyl sulfoxide and the absorbance at 550 nm measured on
a microplate reader.
RT-PCR analysis
Total RNA was isolated from cells using TRIzol reagent
(Invitrogen). Single-strand cDNA for a PCR template was
synthesized from 5 mg of total RNA using random primers and
Moloney murine leukemia virus reverse transcriptase (Promega).
The oligonucleotide primers used for the amplification were: for
human IL-6 (GenBank Accession No. M14584), sense (519–540)
59-GTT CCT GCA GAA AAA GGC AAA G-39 and antisense
(695–716) 59-CTG AGG TGC CCA TGC TAC ATT T-39, with
a product of 198 bp; for human COX-2 (GenBank Accession
No. M90100), sense (574–600) 59-TTC AAA TGA GAT TGT
GGG AAA ATT GCT-39 and antisense (855–878) 59-AGA TCA
TCT CTG CCT GAG TAT CTT-39, with a product of 305 bp;
for human MMP-1 (GenBank Accession No. BC013875), sense
(754–773) 59-CCT AGC TAC ACC TTC AGT GG-39 and
antisense (1072–1091) 59-GCC CAG TAC TTA TTC CCT TT-
39, with a product of 338 bp; for human MMP-13 (GenBank
Accession No. BC067523), sense (1171–1190) 59-TTG AGG ATA
CAG GCA AGA CT-39 and antisense (1462–1481) 59-TGG AAG
TAT TAC CCC AAA TG-39, with a product of 311 bp. b-actin
was used as the internal control; the b-actin primers were sense
(613–632) 59-GAC TAC CTC ATG AAG ATC CT-39 and
antisense (1103–1122) 59-CCA CAT CTG CTG GAA GGT GG-
39, with a product of 510 bp. Equal amounts (1 mg) of each
reverse-transcription product were PCR-amplified using Taq
polymerase and 35 cycles of 1 min at 95uC, 1 min at 58uC, and
1 min at 72uC. The amplified cDNA was run on 1% agarose gels
and visualized under UV light following staining with SYBR Safe
DNA gel stain (Invitrogen).
ELISA assay
FLS (1610
6 cells) were treated with various concentrations of
magnolol for 30 min prior to stimulation with 10 ng/mL of IL-1b
for 24 h in the continued presence of magnolol, then the medium
was collected and assayed for IL-6, PGE2, MMP-1, and MMP-13
using commercial ELISA kits (R&D Systems, Minneapolis, MN,
USA).
Immunoblot analysis
Cells (1610
6) were incubated for 10 min at 4uC in lysis buffer
(20 mM HEPES, pH 7.4, 2 mM EGTA, 50 mM b-glycerophos-
phate, 0.1% Triton X-100, 10% glycerol, 1 mM DTT, 1 mg/mL
of leupeptin, 5 mg/mL of aprotinin, 1 mM phenylmethylsulfonyl
fluoride, and 1 mM sodium orthovanadate), then were scraped off,
incubated on ice for a further 10 min, and centrifuged at 17,000 g
for 30 min at 4uC. The supernatants (60 mg of protein) were
electrophoresed on SDS-PAGE and blotted onto nitrocellulose
membranes. Immunoblot detection was performed with the
corresponding HRP-conjugated antibodies using an ECL detec-
tion kit and exposure to photographic film.
Transfection and reporter gene assay
5610
4 cells in 1 mL of growth medium were seeded in each well
of 24-well plates one day before transfection. Following the
manufacturer’s protocol, 1 mg of plasmid pGL4.32[luc2P/NF-kB-
RE/Hygro] or p5xATF6-GL3, which contains the c-fos promoter,
and 1 mL of TurboFect
TM transfection reagent were mixed for
20 min at room temperature, then were added to the cells and the
mixtures incubated for 24 h at 37uC in a humidified atmosphere
of 5% CO2 in air. Transfection efficiency, determined by
fluorescence microscopy, was .60% in all experiments. For the
reporter gene assay, 100 mL of reporter lysis buffer (Promega) was
added to each well, then the cells were scraped off the dishes,
centrifuged at 17,000 g for 30 s at 4uC, and the supernatants
collected. Aliquots of cell lysates (20 mL) were placed in the wells of
an opaque black 96-well microtiter plate and 40 mL of luciferase
substrate (Promega) added and the luminescence immediately
measured in a microplate luminometer (Beckman Coulter,
Krefeld, Germany).
Electrophoretic mobility shift assays (EMSAs)
Nuclear extracts were prepared and analyzed for DNA-binding
activity of NF-kB and AP-1 using an EMSA Gel Shift Kit
(Affymetrix) as described previously [38]. All procedures were
performed according to the manufacturer’s instructions.
Confocal microscopy assay
Cells on coverslips (1610
4 cells) were fixed in 4% paraformal-
dehyde in phosphate-buffered saline (PBS) for 30 min at room
temperature, then permeabilized with 0.1% Triton X-100 in PBS
for 15 min on ice. Non-specific binding sites were blocked by
incubation with 5% BSA in PBS overnight at 4uC. The coverslips
were then incubated with primary antibodies (1:100) in 0.5% BSA
for 60 min at room temperature. After 3610 min washes in PBS,
the cells were stained for 60 min at room temperature with FITC-
conjugated goat anti-mouse or anti-rabbit IgG antibodies (1:250)
in 0.5% BSA. Stained cultures were viewed and photographed
under a Leica TCS SP5 confocal laser-scanning microscope using
appropriate fluorescence filters.
In vivo adjuvant-induced arthritis (AIA) model
Animal experiments were approved by the Institutional Animal
Care and Use Committee of National Taiwan University College
of Medicine (IACUC number: 20100257). Five-week-old female
Lewis rats were obtained from the National Laboratory Animal
Center (Taipei, Taiwan). Freund’s complete adjuvant (CFA) was
prepared by suspending heat-killed Mycobacterium butyricum (Difco)
in mineral oil at 3 mg/mL. CFA-induced arthritis was induced by
injection of 100 mL of the CFA emulsion intradermally into the
base of the right hind paw on day 0. Magnolol [100 mg/kg
Figure 4. Magnolol suppresses arthritis development in an adjuvant-induced arthritis (AIA) model. After onset of arthritis, rats were
treated with 100 mg/kg magnolol or vehicle (on day 2) for a total of 14 days. (A) Swelling of the ankle joints of both paws were markedly suppressed
by treatment of arthritic rats with 100 mg/kg magnolol, as compared to the vehicle group. (B) Both hind paw volumes of non-treated (basal) rats,
vehicle-treated, and magnolol-treated rats were measured using a digital plethysmometer on the indicated day after AIA induction. (C) Hematoxylin
and eosin staining of tissue specimens from the left ankle joints of vehicle-treated rats and magnolol-treated rats. The specimen from a vehicle-
treated rat exhibits severe synovitis (arrowhead) and leukocyte (arrow) infiltration. Magnolol treatment inhibited both effects. (D) Body weight of non-
treated (basal) rats, vehicle-treated, and magnolol-treated rats measured on the indicated day after AIA induction. (E) Quantification of cytokines in
sera by ELISA on day 16. In (B) and (D), the results are expressed as the mean 6 standard error of the mean (SEM), with n=5. * p,0.05 compared to
the control group; #p,0.05 for the comparison of the indicated groups.
doi:10.1371/journal.pone.0031368.g004
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cremophor, and 90% of a 5% (w/v) solution of glucose in water]
or vehicle was injected intraperitoneally daily from day 2 to day 16
(5 rats per group). On days 0, 2, 6, 9, 13 and 16, the animals were
weighed and both paw volumes measured using a digital
plethysmometer (Diagnostic & Research Instruments CO., Ltd,
Taipei, Taiwan). On day 16, the rats were sacrificed and
underwent histopathological assessments by hematoxylin and
eosin staining of specimens from the left ankle joint.
Data analysis
The data were expressed as the mean 6 standard error of the
mean (SEM) and were analyzed statistically using one-way
ANOVA. When ANOVA showed significant differences between
groups, Tukey post hoc test was used to determine the specific
pairs of groups showing statistically significant differences. A p
value of less than 0.05 was considered statistically significant.
Author Contributions
Conceived and designed the experiments: JHW CRY. Performed the
experiments: YWW ASYC KLW. Analyzed the data: CRY. Contributed
reagents/materials/analysis tools: JHW KSS JPL CLT. Wrote the paper:
CRY.
References
1. Cooles FA, Isaacs JD (2011) Pathophysiology of rheumatoid arthritis. Curr Opin
Rheumatol 23: 233–240.
2. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H (2011) Role
of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev
Rheumatol 7: 33–42.
3. Smolen JS, Steiner G (2003) Therapeutic strategies for rheumatoid arthritis. Nat
Rev Drug Discov 2: 473–488.
4. Scott DL, Wolfe F, Huizinga TWJ (2010) Rheumatoid arthritis. Lancet 376:
1094–1107.
5. Boileau C, Martel-Pelletier J, Caron J, Msika P, Guillou GB, et al. (2009)
Protective effects of total fraction of avocado/soybean unsaponifiables on the
structural changes in experimental dog osteoarthritis: inhibition of nitric oxide
synthase and matrix metalloproteinase-13. Arthritis Res Ther 11: R41.
6. Gaby AR (1999) Alternative treatments for rheumatoid arthritis. Altern Med
Rev 4: 392–402.
7. Jacobs JWG, Kraaimaat FW, Bijlsma JW (2001) Why do patients with
rheumatoid arthritis use alternative treatments? Clin Rheumatol 20: 192–196.
8. Lee YJ, Lee YM, Lee CK, Jung JK, Han SB, et al. (2011) Therapeutic
applications of compounds in the Magnolia family. Pharmacol Ther 130:
157–176.
9. Seventy-third meeting of the Joint FAO/WHO Expert Committee on Food
Additive (JECFA) (2011) Safety evaluation of certain food additives and
contaminants. WHO Food Additives Series. pp 64.
10. Wang JP, Ho TF, Chang LC, Chen CC (1995) Anti-inflammatory effect of
magnolol, isolated from Magnolia officinalis, on A23187-induced pleurisy in
mice. J Pharm Pharmacol 47: 857–860.
11. Teng CM, Ko FN, Wang JP, Lin CN, Wu TS, et al. (1991) Antihaemostatic and
antithrombotic effect of some antiplatelet agents isolated from Chinese herbs.
J Pharm Pharmacol 43: 667–669.
12. Hwang ES, Park KK (2010) Magnolol suppresses metastasis via inhibition of
invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human
prostate carcinoma cells. Biosci Biotechnol Biochem 74: 961–967.
13. Chen LC, Liu YC, Liang YC, Ho YS, Lee WS (2009) Magnolol inhibits human
glioblastoma cell proliferation through upregulation of p21/Cip1. J Agric Food
Chem 57: 7331–7337.
14. Teng CM, Yu SM, Chen CC, Huang YL, Huang TF (1990) EDRF-release and
Ca+(+)-channel blockade by magnolol, an antiplatelet agent isolated from
Chinese herb Magnolia officinalis, in rat thoracic aorta. Life Sci 47: 1153–1161.
15. Tsai YC, Cheng PY, Kung CW, Peng YJ, Ke TH, et al. (2010) Beneficial effects
of magnolol in a rodent model of endotoxin shock. Eur J Pharmacol 641: 67–73.
16. Matsuda H, Kageura T, Oda M, Morikawa T, Sakamoto Y, et al. (2001) Effects
of constituents from the bark of Magnolia obovata on nitric oxide production in
lipopolysaccharide-activated macrophages. Chem Pharm Bull 49: 716–720.
17. Schuhly W, Khan SI, Fischer NH (2009) Neolignans from North American
Magnolia species with cyclooxygenase 2 inhibitory activity. Inflammopharmacology
17: 106–110.
18. Chen YH, Lin SJ, Chen JW, Ku HH, Chen YL (2002) Magnolol attenuates
VCAM-1 expression in vitro in TNF-a-treated human aortic endothelial cells
and in vivo in the aorta of cholesterol-fed rabbits. Br J Pharmacol 135: 37–47.
19. Tse AK, Wan CK, Zhu GY, SHen XL, Cheung HY, et al. (2007) Magnolol
suppresses NF-kB activation and NF-kB regulated gene expression through
inhibition of IkB kinase activation. Mol Immunol 44: 2647–2658.
20. Park J, Lee J, Jung E, Park Y, Kim K, et al. (2004) In vitro antibacterial and anti-
inflammatory effects of honokiol and magnolol against Propionibacterium sp.
Eur J Pharmacol 496: 189–195.
21. Barksby HE, Lea SR, Preshaw PM, Taylor JJ (2007) The expanding family of
interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin
Exp Immunol 149: 217–225.
22. Daheshia M, Yao JQ (2008) The interleukin 1b pathway in the pathogenesis of
osteoarthritis. J Rheumatol 35: 2306–2312.
23. Lin YR, Chen HH, Lin YC, Ko CH, Chan MH (2009) Antinociceptive actions
of honokiol and magnolol on glutamatergic and inflammatory pain. J Biomed
Sci 16: 94.
24. Kim KR, Park KK, Chun KS, Chung WY (2010) Honokiol inhibits the
progression of collagen-induced arthritis by reducing levels of pro-inflammatory
cytokines and matrix metalloproteinases and blocking oxidative tissue damage.
J Pharmacol Sci 114: 69–78.
25. Kao YH, Jawan B, Sun CK, Goto S, Lin YC, et al. (2010) High concentration of
magnolol induces hepatotoxicity under serum-reduced conditions. Phytomedi-
cine 17: 469–474.
26. Jawan B, Goto S, Pan TL, Lai CY, Luk HN, et al. (2003) The protective
mechanism of magnolol, a Chinese herb drug, against warm ischemia-
reperfusion injury of rat liver. J Surg Res 110: 378–382.
27. Suleyman H, Albayrak A, Bilici M, Cadirci E, Halici Z (2010) Different
mechanisms in information and prevention of indomethacin-induced gastric
ulcers. Inflammation 33: 224–234.
28. Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, et al. (2002) Is
NF-kB a useful therapeutic target in rheumatoid arthritis? Ann Rheum Dis 61
S2: ii13–18.
29. Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, et al.
(2005) NF-kB-inducing kinase controls lymphocyte and osteoclast activities in
inflammatory arthritis. J Clin Invest 115: 1848–1854.
30. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, et al. (2010) Efficacy
and safety of MerivaH, a curcumin-phosphatidylcholine complex, during
extended administration in osteoarthritis patients. Altern Med Rev 15: 337–344.
31. Aikawa Y, Morimoto K, Yamamoto T, Chaki H, Hashiramoto A, et al. (2008)
Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat
Biotech 26: 817–823.
32. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ (1995) Integration of MAPK
kinase signal transcription pathways at the serum response element. Science 269:
403–407.
33. Dayer JM (2003) The pivotal role of interleukin-1 in the clinical manifestations
of rheumatoid arthritis. Rheumatology 42 S2: ii3–10.
34. Kim HM, Bae SJ, Kim DW, Kim BK, Lee SB, et al. (2007) Inhibitory role of
magnolol on proliferative capacity and matrix metalloproteinase-9 expression in
TNF-a-induced vascular smooth muscle cells. Int Immunopharmacol 7:
1083–1091.
35. Holoshitz J, Naparstek Y, Ben-Nun A, Cohen IR (1983) Lines of T lymphocytes
induce or vaccinate against autoimmune arthritis. Science 219: 56–58.
36. Barsante MM, Roffe E, Yokoro CM, Tafuri WL, Souza DG, et al. (2005) Anti-
inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-
induced arthritis. Eur J Pharmacol 516: 282–289.
37. Shen YC, Sung YK, Chen CF (1998) Magnolol inhibits Mac-1 (CD11b/CD18)-
dependent neutrophil adhesion: relationship with its antioxidant effect.
Eur J Pharmacol 343: 79–86.
38. Chen PH, Yang CR (2008) Decoy receptor 3 expression in AsPC-1 human
pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-,
and NF-kB-dependent pathway. J Immunol 181: 8441–8449.
Figure 5. Chemical structure of magnolol.
doi:10.1371/journal.pone.0031368.g005
Magnolol Acts as a Potent Anti-Arthritic Agent
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31368